CA2381771A1 - Procedes et compositions relatifs aux sous-unites .beta.1a de canaux sodiques - Google Patents

Procedes et compositions relatifs aux sous-unites .beta.1a de canaux sodiques Download PDF

Info

Publication number
CA2381771A1
CA2381771A1 CA002381771A CA2381771A CA2381771A1 CA 2381771 A1 CA2381771 A1 CA 2381771A1 CA 002381771 A CA002381771 A CA 002381771A CA 2381771 A CA2381771 A CA 2381771A CA 2381771 A1 CA2381771 A1 CA 2381771A1
Authority
CA
Canada
Prior art keywords
sodium channel
subunit
cell
beta
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002381771A
Other languages
English (en)
Inventor
Lori L. Isom
Kristin Kazen-Gillespie
Kathryn E. Rogers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Ortho McNeil Pharmaceutical Inc
University of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Pharmaceutical Inc, University of Michigan filed Critical Ortho McNeil Pharmaceutical Inc
Publication of CA2381771A1 publication Critical patent/CA2381771A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne une nouvelle sous-unité de canaux sodiques sensibles au voltage. Cette sous-unité est un variant d'épissure de la sous-unité .beta. de canaux sodiques codant une nouvelle protéine. En outre, cette invention concerne des procédés et des compositions d'utilisation des acides nucléiques et protéines de cette sous-unité.
CA002381771A 1999-09-30 2000-09-29 Procedes et compositions relatifs aux sous-unites .beta.1a de canaux sodiques Abandoned CA2381771A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15683799P 1999-09-30 1999-09-30
US60/156,837 1999-09-30
PCT/US2000/027119 WO2001023571A1 (fr) 1999-09-30 2000-09-29 PROCEDES ET COMPOSITIONS RELATIFS AUX SOUS-UNITES β1A DE CANAUX SODIQUES

Publications (1)

Publication Number Publication Date
CA2381771A1 true CA2381771A1 (fr) 2001-04-05

Family

ID=22561303

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002381771A Abandoned CA2381771A1 (fr) 1999-09-30 2000-09-29 Procedes et compositions relatifs aux sous-unites .beta.1a de canaux sodiques

Country Status (5)

Country Link
EP (1) EP1216300A1 (fr)
JP (1) JP2003510079A (fr)
AU (2) AU7743500A (fr)
CA (1) CA2381771A1 (fr)
WO (2) WO2001023570A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2411069A1 (fr) 2000-06-07 2001-12-13 Ortho-Mcneil Pharmaceutical, Inc. Sous-unites beta-1a humaines du canal sodium electriquement potentialise et procedes d'utilisation
SI1458386T1 (sl) 2001-12-27 2007-08-31 Ortho Mcneil Pharm Inc Aroil pirol heteroeril in metanoli, uporabni za zdravljenje motnje centralnega živčnega sistema
DE60224002T2 (de) * 2002-02-14 2008-11-06 Biofrontera Pharmaceuticals Ag Kathepsin Y Inhibitoren für die Entwicklung von Medikamenten zur Schmerzbehandlung

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1171589A1 (fr) * 1999-04-15 2002-01-16 Cambridge University Technical Services Limited Nouvelle famille de proteines sous-unite g(b) du canal sodique potentio-dependant, acides nucleiques codant pour elles et leur utilisation a des fins therapeutiques et diagnostiques
AU5010900A (en) * 1999-05-14 2000-12-05 Millennium Pharmaceuticals, Inc. Gene encoding a sodium channel beta-3 subunit protein

Also Published As

Publication number Publication date
AU7743500A (en) 2001-04-30
AU7746100A (en) 2001-04-30
EP1216300A1 (fr) 2002-06-26
JP2003510079A (ja) 2003-03-18
WO2001023570A2 (fr) 2001-04-05
WO2001023570A3 (fr) 2001-10-25
WO2001023571A1 (fr) 2001-04-05

Similar Documents

Publication Publication Date Title
US11932908B2 (en) Compositions and methods for diagnosis and treatment of epilepsy
US6790648B2 (en) DNA fragmentation factor involved in apoptosis
US20040260058A1 (en) Novel endothelially expressed dnas and proteins, and their use
US7229816B2 (en) Sitosterolemia susceptibility gene (SSG) polypeptides
CA2381771A1 (fr) Procedes et compositions relatifs aux sous-unites .beta.1a de canaux sodiques
US20050032155A1 (en) Mutation in the beta2 nicotinic acetycholine receptor subunit associated with nocturnal frontal lobe epilepsy
CA2325663A1 (fr) Nouvelles mutations dans le gene freac3 pour le diagnostic et le pronostique du glaucome et de la dysgenesie du segment anterieur
US20040191791A1 (en) Novel mutation
CA2285631A1 (fr) Proteine anti-oxydante 2, gene et procedes d'utilisation correspondants
US20090233986A1 (en) Methods and compositions for using sax2
WO2001016315A1 (fr) Transporteur de choline a forte activite
US20020142417A1 (en) Antioxidant protein 2, gene and methods of use therefor
US20030144205A1 (en) Novel germ cell-specific contraceptive target
US20030082650A1 (en) Great gene and protein
US20060079674A1 (en) Contraceptive targets
US20030118990A1 (en) Novel estrogen-regulated G protein gamma subunit: compositions and methods of use
US20020099190A1 (en) Estrogen-regulated unconventional myosin-related protein: compositions and methods of use
AU2002252833A1 (en) Novel mutation
JP2004121246A (ja) 神経変性疾患の予防・治療剤
WO2001068880A9 (fr) Meso-inositol phosphate synthase regulee par estrogenes : compositions et methodes d'utilisation
AU2003228675A1 (en) Contraceptive targets

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20040510